Pharmacological inhibition of the LIF/LIFR autocrine loop reveals vulnerability of ovarian cancer cells to ferroptosisNPJ PRECISION ONCOLOGYIF82024-05-243OAAI
Pharmacological inhibition of the LIF-LIFR autocrine loop reveals vulnerability of ovarian cancer to ferroptosisCANCER RESEARCHIF16.62024-03-220PRE
Preclinical evaluation of ERX-208, a potent inducer of ER stress for the treatment of ovarian cancerCANCER RESEARCHIF16.62024-03-220PRE
Novel LIPA targeted therapy for treating inflammatory breast cancerCANCER RESEARCHIF16.62024-03-220PRE
Effectiveness of TruScreen for detecting CIN2+in women with ThinPrep cytologic test results indicating atypical squamous cells of undetermined significance and low-grade squamous intraepithelial lesionsFUTURE ONCOLOGYIF2.62023-12-060PRE
Preclinical Development of Brain Permeable ERβ Agonist for the Treatment of GlioblastomaMOLECULAR CANCER THERAPEUTICSIF5.52023-07-254OA
The role of PELP1 inhibitor SMIP34 in the treatment of endometrial cancerCANCER RESEARCHIF16.62023-04-040PRE
Targeting LIF/LIFR autocrine loops with EC359 in ovarian cancer: A novel LIFR targeted therapyCANCER RESEARCHIF16.62023-04-040PRE
The role of obesity in promoting the LIF/LIFR signaling in triple negative breast cancerCANCER RESEARCHIF16.62023-04-040PRE
ERX-208 as a novel therapeutic for treating ovarian cancer by enhancing endoplasmic reticulum stressCANCER RESEARCHIF16.62023-04-040PRE